Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 9월 04

Hemab Therapeutics Holdings Inc

COAGNASDAQ
Trade with Public
Trade with Public
$44.37
-0.33-0.74%
가까이에: Sep 3, 5:00 PM EST
$44.37
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Hemab Therapeutics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Hemab Therapeutics Hldgs (COAG).

Price Target Range — 2 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$51Upside to Avg. PT+15.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026WedbushDavid NierengartenPT RaiseOutperform$55→$64
Aug 11, 2026HC Wainwright & Co.Emily BodnarPT RaiseBuy$52→$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.
Benzinga Newsdesk

PRO
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved